It’s all about GLP-1s on this week’s episode. For the Trends segment, we’re continuing the GLP-1 focus with an update on how Eli Lilly is overtaking Novo Nordisk in the diabetes and obesity treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback